🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

16 results for “IO Biotech” Clear

  1. IO102-IO103

    IO Biotech

    Metastatic Melanoma

    phase 3 small molecule active

    1 trial

  2. KEYTRUDA 25 mg/mL concentrate for solution for infusion, IO102-IO103

    IO Biotech

    Previously untreated, unresectable, or metastatic melanoma

    phase 3 small molecule active

    1 trial

  3. IO102

    IO Biotech

    NSCLC

    phase 2 mab completed

    1 trial

  4. IO102-IO103 in combination with pembrolizumab

    IO Biotech

    Lung Cancer Non Small Cell

    phase 2 small molecule completed

    1 trial

  5. IO102-IO103, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    IO Biotech

    Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC), Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  6. IO102/IO103

    IO Biotech

    Melanoma

    phase 2 small molecule active

    2 trials

  7. IRX4204

    IO Biotech

    Psoriasis

    phase 2 small molecule on hold

    1 trial

  8. NRX 194204

    IO Biotech

    Castration Resistant Prostate Cancer

    phase 2 small molecule completed

    1 trial

  9. PD-L1 peptide

    IO Biotech

    Smoldering Multiple Myeloma

    phase 2 mab terminated

    1 trial

  10. PD-L1, PD-L2 peptides with Montanide ISA51

    IO Biotech

    Chronic Lymphocytic Leukemia

    phase 2 other completed

    1 trial

  11. Pembrolizumab

    IO Biotech

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  12. A study to assess safety and efficacy of SOT201 in patients with advance/metastatic cancer

    IO Biotech

    advanced/metastatic solid tumors

    phase 1 other active

    1 trial

  13. IRX4204

    IO Biotech

    Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  14. IRX4204

    IO Biotech

    Lung Cancer, Nonsmall Cell

    phase 1 small molecule terminated

    1 trial

  15. IRX5183

    IO Biotech

    Acute Myeloid Leukemia (AML)

    phase 1 small molecule terminated

    1 trial

  16. PD-L1/IDO Peptide Vaccine

    IO Biotech

    High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

    phase 1 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources